摘要
目的探讨小儿消积止咳口服液辅助个体抗感染和对症治疗儿童重症社区获得性肺炎的效果。方法采用前瞻性对照研究设计,选择2023年4月至2025年3月于宝鸡市妇幼保健院治疗的重症社区获得性肺炎患儿100例,采用计算机生成的随机数字序列进行分组,每组50例,其中对照组停止治疗2例,失访1例,观察组失访3例,最终两组各47例。对照组根据病原类型进行抗感染和对症治疗;观察组在对照组基础上增加小儿消积止咳口服液治疗。比较两组治疗前后临床疗效、呼吸道症状消失时间、中医证候积分、炎症因子水平以及不良反应发生率。结果治疗7 d后,观察组总有效率95.74%(45/47)高于对照组78.72%(37/47)(χ^(2)=6.114,P=0.013)。观察组发烧、咳嗽咳痰、肺部啰音消失时间[分别为(2.24±1.21)、(3.77±0.98)、(4.61±1.12)d]短于对照组[分别为(3.37±1.81)、(4.32±1.33)、(5.24±1.03)d](t=3.558、2.282、2.838,均P<0.05)。观察组发热、喘息、咳嗽、腹胀、乏力、头晕积分[分别为(1.31±0.35)、(1.36±0.29)、(1.29±0.38)、(0.66±0.23)、(0.73±0.27)、(0.69±0.25)分]低于对照组[分别为(2.45±0.37)、(2.56±0.31)、(2.48±0.38)、(1.47±0.28)、(1.37±0.24)、(1.35±0.21)分](t=15.345、19.380、15.181、15.325、12.146、13.858,均P<0.05)。观察组中性粒细胞比例、血清白细胞介素6、C反应蛋白水平[分别为(45.68±8.45)%、(53.12±1.31)pg/L、(13.03±1.98)mg/L]低于对照组[分别为(49.65±9.28)%、(55.21±1.19)pg/L、(16.89±2.01)mg/L](t=2.169、8.096、9.379,均P<0.05)。不良反应发生率,观察组12.77%(6/47)与对照组17.02%(8/47)比较,差异无统计学意义(χ^(2)=0.336,P=0.562)。结论小儿消积止咳口服液辅助抗感染方案,能缓解重症社区获得性肺炎患儿临床症状,加快呼吸道功能恢复,降低机体炎症反应水平,安全性良好。
Objective To explore the clinical efficacy of Xiao’er Xiaoji Zhike Oral Liquid as an adjunct to individualized anti-infection regimens in children with severe community-acquired pneumonia(SCAP).Methods A prospective controlled study design was adopted.A total of 100 children with SCAP treated at Baoji Maternal and Child Health Hospital from April 2023 to March 2025 were selected and randomly assigned into two groups using a computer-generated random number sequence(50 cases each).Two cases in the control group discontinued treatment and one was lost to follow-up,while three cases in the observation group were lost to follow-up.Ultimately,both groups comprised 47 cases each.The control group received an individualized basic treatment regimen based on pathogen types,and the observation group additionally received Xiao’er Xiaoji Zhike Oral Liquid.The clinical efficacy,recovery time of respiratory symptoms,Traditional Chinese Medicine(TCM)syndrome scores,levels of inflammatory factors and incidence of adverse reactions were compared between the two groups before and after treatment.Results After 7 days of treatment,the total effective rate in observation group was 95.74%(45/47),higher than that in the control group(78.72%(37/47))(χ^(2)=6.114,P=0.013).The recovery times for fever,cough and expectoration,and pulmonary rales in the observation group((2.24±1.21),(3.77±0.98),(4.61±1.12)days,respectively)were shorter than those in the control group((3.37±1.81),(4.32±1.33),and(5.24±1.03)days,respectively)(t=3.558,2.282,2.838,all P<0.05).TCM syndrome scores for fever,wheezing,cough frequency,abdominal distension,fatigue and dizziness in the observation group((1.31±0.35),(1.36±0.29),(1.29±0.38),(0.66±0.23),(0.73±0.27),(0.69±0.25)points,respectively)were lower than those in the control group((2.45±0.37),(2.56±0.31),(2.48±0.38),(1.47±0.28),(1.37±0.24),(1.35±0.21)points,respectively)(t=15.345,19.380,15.181,15.325,12.146,13.858,all P<0.05).The proportion of neutrophils,the levels of serum interleukin-6 and C-reactive protein in the observation group((45.68±8.45)%,(53.12±1.31)pg/L,(13.03±1.98)mg/L,respectively)were lower than those in the control group((49.65±9.28)%,(55.21±1.19)pg/L,(16.89±2.01)mg/L,respectively)(t=2.169,8.096,9.379,all P<0.05).The incidence of adverse reactions was 12.77%(6/47)in the observation group and 17.02%(8/47)in the control group,with no statistically significant difference(χ^(2)=0.336,P=0.562).Conclusion Xiao’er Xiaoji Zhike Oral Liquid as an adjunct to individualized anti-infection therapy can alleviate the clinical symptoms in children with SCAP,accelerate the recovery of respiratory function,reduce systemic inflammatory response,and exhibit a favorable safety profile.
作者
刘晶
吕明
LIU Jing;LYU Ming(Department of Pediatric Infectious Diseases,Baoji Maternal and Child Health Hospital,Baoji 721000,China;Department of Pediatric Gastroenterology and Nutrition,Baoji Maternal and Child Health Hospital,Baoji 721000,China)
出处
《中国药物应用与监测》
2026年第2期272-276,共5页
Chinese Journal of Drug Application and Monitoring
关键词
儿童社区获得性肺炎
小儿消积止咳口服液
临床疗效
炎症因子
community acquired pneumonia
Xiao’er Xiaoji Zhike Oral Liquid
clinical efficacy
inflammatory factors
